Drug intelligence / Profile preview

A009

Development stage
Preclinical
Lead developer
Fattoria La Vialla
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

A009 is a purified, polyphenol-rich extract derived from olive mill wastewater (OMWW), a byproduct generated during extra-virgin olive oil (EVOO) processing. It is highly enriched in soluble polyphenols, with hydroxytyrosol being the most abundant component, alongside verbascoside and oleuropein. Developed through a collaboration involving the agricultural producer Azienda Agricola-Fattoria La Vialla and academic institutions such as IRCCS MultiMedica and the University of Insubria, A009 is being investigated for its chemopreventive, anti-angiogenic, and cardioprotective properties. In preclinical models, A009 has demonstrated the ability to inhibit the proliferation, migration, and invasion of breast, colon, lung, and prostate cancer cells. Furthermore, in cardio-oncology studies, A009 has shown significant potential to mitigate chemotherapy-induced cardiotoxicity (such as that caused by doxorubicin, cisplatin, and 5-fluorouracil) without compromising the anti-tumor efficacy of the chemotherapeutic agents.

Other names
OMWW extractolive mill wastewater extractpolyphenol-rich olive mill wastewater extract
02

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)CCL2 (C-C motif chemokine 2)CXCR4 (C-X-C motif chemokine receptor 4)Interleukin-6/Signal transducer and activator of transcription 3 signaling axisVEGFA (Vascular endothelial growth factor A)CDKN2A (Cyclin-dependent kinase inhibitor 2A)CXCL12 (C-X-C motif chemokine ligand 12)

Beyond the preview

Go deeper on A009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on A009.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call